Notice2024-06612
National Institute on Drug Abuse; Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 28, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 61 (Thursday, March 28, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 61 (Thursday, March 28, 2024)]
[Notices]
[Page 21526]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-06612]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
This will be a hybrid meeting held in-person and virtually and will
be open to the public, as indicated below, with attendance limited to
space available. Individuals who plan to attend in-person or view the
virtual meeting and need special assistance such as sign language
interpretation or other reasonable accommodations, should notify Dr.
Jeanette Marketon via email at <a href="/cdn-cgi/l/email-protection#f19b94909f94858594df9c90839a94859e9fb19f9899df969e87"><span class="__cf_email__" data-cfemail="9df7f8fcf3f8e9e9f8b3f0fceff6f8e9f2f3ddf3f4f5b3faf2eb">[email protected]</span></a> five days in
advance of the meeting. The open session of the meeting can be accessed
from the NIH Videocast at the following link: <a href="https://videocast.nih.gov/">https://videocast.nih.gov/</a>.
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6),
Title 5 U.S.C., as amended. The grant applications and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: May 7, 2024.
Closed: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant applications.
Open: 12:45 p.m. to 5:00 p.m.
Agenda: Presentations and other business of the Council.
Place: Neuroscience Center, Conference Room 1155/1145, National
Institutes of Health, 6001 Executive Boulevard, Rockville, MD 20852
(Hybrid Meeting).
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown
Street, Bethesda, MD 20852, 301-443-6480, <a href="/cdn-cgi/l/email-protection#b6c5c1d3dfc5c5f6d8dfd2d798d8dfde98d1d9c0"><span class="__cf_email__" data-cfemail="394a4e5c504a4a7957505d5817575051175e564f">[email protected]</span></a>.
Contact Person: Jeanette Marketon, Ph.D., PMP Director, Office
of Extramural Policy. Division of Extramural Research, Office of
Extramural Policy, National Institute on Drug Abuse, NIH, Three
White Flint North, RM 09C71, 11601 Landsdown Street, Bethesda, MD
20852, 301-443-5239, <a href="/cdn-cgi/l/email-protection#0c66696d626978786922616d7e67697863624c626564226b637a"><span class="__cf_email__" data-cfemail="c9a3aca8a7acbdbdace7a4a8bba2acbda6a789a7a0a1e7aea6bf">[email protected]</span></a>.
Any interested person may file written comments with the committee
by forwarding the statement to Dr. Jeanette Marketon via email at
<a href="/cdn-cgi/l/email-protection#412b24202f243535246f2c20332a24352e2f012f28296f262e37"><span class="__cf_email__" data-cfemail="e9838c88878c9d9d8cc784889b828c9d8687a9878081c78e869f">[email protected]</span></a>. The statement should include the name,
address, telephone number and when applicable, the business or
professional affiliation of the interested person.
In the interest of security, NIH has procedures at <a href="https://www.nih.gov/about-nih/visitor-information/campus-access-security">https://www.nih.gov/about-nih/visitor-information/campus-access-security</a> for
entrance into on-campus and off-campus facilities. All visitor
vehicles, including taxicabs, hotel, and airport shuttles will be
inspected before being allowed on campus. Visitors attending a meeting
on campus or at an off-campus federal facility will be asked to show
one form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: <a href="http://www.drugabuse.gov/NACDA/NACDAHome.html">www.drugabuse.gov/NACDA/NACDAHome.html</a>, where an agenda and any
additional information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-06612 Filed 3-27-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 28, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.